SKYA vs MCK vs BAX Stock Comparison

SkyAI, Mckesson and Baxter International Prices as of Oct 26, 2026 Peers: Industry group
SKYA SkyAI, Inc.
$2.89 +53.7% 1M -42.8% 1Y
Market cap
$210.15M
P/E
–
Revenue (TTM)
$194.22K
Div. yield
–
Medical Supplies Healthcare
2 wins
MCK Mckesson Corp
$992.64 +14.5% 1M +23.8% 1Y
Market cap
$114.87B
P/E
25.0x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
8 wins
BAX Baxter International Inc
$25.29 +8.2% 1M +9.9% 1Y
Market cap
$12.89B
P/E
–
Revenue (TTM)
$5.55B
Div. yield
0.01%
Medical Supplies Healthcare
1 win

Head to Head

11 decided of 12

Mckesson leads on 8 of the 12 questions below (Mckesson 8, SkyAI 2, Baxter International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSKYAMCKBAXLeader
Larger companyMarket capitalisation $210.15M $114.87B $12.89B MCK
Cheaper on earningsLower P/E, profitable companies only -0.7x 25.0x -12.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 0.0x 21.1x 12.8x SKYA
Faster revenue growthRevenue growth, trailing twelve months +108.9% +8.8% -49.1% SKYA
More profitableNet margin, trailing twelve months -158,431.4% 1.1% -19.2% MCK
Better return on capitalReturn on invested capital — 107.9% 3.4% MCK
Less leveragedLower net debt / EBITDA — 0.6x 4.8x MCK
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% BAX
Better 1-year returnPrice return, last 12 months -42.8% +23.8% +9.9% MCK
Better 5-year returnAnnualised price return, 5 years — +37.4%/yr -21.0%/yr MCK
Less volatileAnnualised volatility, 1 year 106.2% 30.7% 44.4% MCK
Higher overall scoreMean of the five percentile scores vs peers 26/100 58/100 44/100 MCK

Percentile Scorecard

SKYAMCKBAX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSKYAMCKBAX
Valuation 2 #223 of 228 50 #13 of 25 82 #41 of 228
Growth 6 #207 of 221 65 #9 of 24 19 #180 of 221
Profitability 1 #206 of 208 65 #9 of 24 73 #57 of 208
Financial Health 94 #16 of 239 48 #14 of 26 19 #194 of 239
Shareholder Returns – 60 #7 of 16 27 #101 of 137
Overall 26 58 44
  • SKYA ranked among 248 companies in Medical Devices and Diagnostics
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • BAX ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSKYAMCKBAXSPY
1 month +53.7%+14.5%+8.2% -0.8%
3 months +118.9%+16.7%+8.4% +3.5%
6 months +61.5%+19.8%+36.8% +7.0%
Year to date +42.4%+21.0%+32.3% +12.2%
1 year -42.8%+23.8%+9.9% +13.0%
3 years -99.9%+121.6%-21.4% +86.3%
3 years, per year -90.1%+30.4%-7.7% +23.1%
5 years —+388.9%-69.1% +68.6%
5 years, per year —+37.4%-21.0% +11.0%
10 years —+526.0%-46.7% +258.0%
10 years, per year —+20.1%-6.1% +13.6%

Risk

MeasureSKYAMCKBAXSPY
Volatility, 1Y 106.2%30.7%44.4% 12.7%
Downside volatility, 1Y 104.5%27.3%48.2% 12.7%
Beta vs S&P 500, 1Y 2.59-0.261.16 1.00
Return / volatility, 1Y -0.400.780.22 1.02
Max drawdown, 5Y -100.0%-27.2%-82.3% -25.4%
From 52-week high -46.6%-3.6%-10.8% -1.8%
52-week high $5.41$1,030.18$28.35 $779.14
52-week low $0.95$725.17$15.80 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSKYAMCKBAX
P/E now vs peer median -0.7xmedian 30.6x 25.7xmedian 24.3x -12.3xmedian 30.6x
P/S now vs peer median 1,073xmedian 3.0x 0.3xmedian 0.3x 2.4xmedian 3.0x
EV/EBITDA now vs peer median —median 17.5x 16.6xmedian 13.5x 13.5xmedian 17.5x
P/FCF now vs peer median —median 23.3x 18.0xmedian 15.6x 15.6xmedian 23.3x
P/B now vs peer median 1.3xmedian 2.4x -27.3xmedian 2.5x 2.1xmedian 2.4x
PEG now vs peer median 0.01median 0.87 2.15median 1.33 -0.43median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSKYAMCKBAX
Revenue $194.22K $410.98B $5.55B
Gross profit $321.93K $14.96B $3.78B
Operating income -$289.52M $6.50B $532.00M
Net income -$307.71M $5.30B -$1.06B
Free cash flow – $6.42B $839.00M
R&D $399.91K – $542.00M
EPS (diluted) $-4.27 $38.52 $-2.05
Cash & equivalents $12.07M $5.16B $2.15B
Total debt – $9.73B $9.46B
Shares (diluted) 72.09M 119.20M 518.00M
Enterprise value $168.85M $98.77B $5.02B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSKYAMCKBAX
P/E -0.7x 25.7x -12.3x
P/FCF – 18.0x 15.6x
P/Operating cash flow – 16.9x 9.7x
P/S 1,073x 0.3x 2.4x
P/B 1.3x -27.3x 2.1x
P/Tangible book 16.0x -14.0x 6.1x
EV/EBITDA – 16.6x 13.5x
EV/EBIT -0.7x 18.5x 38.3x
EV/Revenue 1,011x 0.3x 3.7x
EV/FCF – 18.8x 24.3x
EV/Operating cash flow – 17.6x 15.2x
PEG (3Y EPS CAGR) 0.01 2.15 -0.43

Growth

14 metrics
MetricSKYAMCKBAX
Revenue growth (1Y) 108.9% 8.8% -49.1%
Revenue CAGR (3Y) 23.8% 13.1% -23.5%
Gross profit growth (1Y) – 11.2% -1.8%
Gross profit CAGR (3Y) – 6.6% -5.2%
Operating income growth (1Y) -5,525% 46.6% -50.8%
Operating income CAGR (3Y) -212.8% 13.5% 29.5%
Net income growth (1Y) -42,440% 58.1% -604.0%
Net income CAGR (3Y) -238.0% 10.7% 28.0%
EPS growth (1Y) -487.2% 52.8% -580.5%
EPS CAGR (3Y) -84.2% 12.0% 28.6%
Operating cash flow growth (1Y) – 4.7% 56.3%
Operating cash flow CAGR (3Y) – 10.7% -4.8%
Free cash flow growth (1Y) – 6.8% 153.5%
Free cash flow CAGR (3Y) – 11.3% -9.5%

Profitability

14 metrics
MetricSKYAMCKBAX
Gross margin 165.8% 3.6% 68.1%
EBITDA margin – 1.8% 27.3%
Operating margin -149,065% 1.6% 9.6%
Pretax margin -151,352% 1.6% 5.1%
Net margin -158,431% 1.1% -19.2%
FCF margin – 1.6% 15.1%
Operating cash flow margin – 1.7% 24.2%
Return on equity -140.2% – -17.4%
Return on assets -137.6% 6.2% -5.4%
Return on invested capital – 107.9% 3.4%
Return on capital employed -136.7% 43.4% 3.3%
Asset turnover 0.0x 4.8x 0.3x
Cash conversion (OCF / net income) – 1.3x -1.3x
Stock comp / revenue 48,037% – 2.1%

Financial Health

11 metrics
MetricSKYAMCKBAX
Debt / assets – 11.0% 47.8%
Debt / equity – -2.3x 1.5x
Net debt / EBITDA – 0.6x 4.8x
Debt / FCF – 1.5x 11.3x
Liabilities / assets 1.9% 104.8% 68.6%
Equity / assets 98.1% -4.8% 31.4%
Interest coverage – 23.6x –
Current ratio 5.3x 0.9x 1.9x
Quick ratio 4.4x 0.5x 1.1x
Cash ratio 4.2x 0.1x 0.6x
Altman Z-score 31.13 5.90 2.13

Shareholder Returns

7 metrics
MetricSKYAMCKBAX
Dividend yield – 0.3% 0.2%
Net buyback yield – 5.7% -0.2%
Shareholder yield – 6.1% 0.0%
Payout ratio (earnings) – 7.4% -17.3%
Payout ratio (FCF) – 6.1% 21.9%
Dividend growth (1Y) – 11.3% -60.8%
Dividend CAGR (3Y) – 10.0% -32.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSKYAMCKBAX
Forward P/E 0.0xFY2026 21.1xFY2026 12.8xFY2026
EPS, next fiscal year $2,362.06FY2026 $47.15FY2026 $1.98FY2026
EPS growth, next FY – +20.6%FY2026 -10.4%FY2026
EPS growth, the year after – +11.0% -3.5%
Revenue, next fiscal year $70.01MFY2026 $444.47BFY2026 $11.05BFY2026
Revenue growth, next FY +34,200.1%FY2026 +10.2%FY2026 -1.7%FY2026
Revenue growth, the year after +17.5% +1.5% +11.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSKYAMCKBAX
Held by institutions – 89.1% 100.0%
Institutions holding – 2,007 690
Change in shares held, QoQ – -0.7% +5.2%
Institutions buying – 879 359
Institutions selling – 791 193
Buyers to sellers – 1.11 1.86

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SKYAMCKBAX
SKYA 1.00 -0.11 0.11
MCK -0.11 1.00 0.16
BAX 0.11 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SKYA, MCK and BAX?

Mckesson (MCK) is the largest by market capitalisation: SkyAI (SKYA) $210.15M, Mckesson (MCK) $114.87B, Baxter International (BAX) $12.89B.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: SkyAI (SKYA) +108.9%, Mckesson (MCK) +8.8%, Baxter International (BAX) -49.1%.

Which company is more profitable?

Mckesson (MCK) has the highest net margin (SkyAI (SKYA) -158,431.4%, Mckesson (MCK) 1.1%, Baxter International (BAX) -19.2%). On return on invested capital, Mckesson (MCK) leads (Mckesson (MCK) 107.9%, Baxter International (BAX) 3.4%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: SkyAI (SKYA) -42.8%, Mckesson (MCK) +23.8%, Baxter International (BAX) +9.9%. Over five years, Mckesson (MCK) compounded fastest (Mckesson (MCK) +37.4%/yr, Baxter International (BAX) -21.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Baxter International (BAX) has the highest dividend yield: SkyAI (SKYA) 0.00%, Mckesson (MCK) 0.00%, Baxter International (BAX) 0.01%. SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (SkyAI (SKYA) 106.2%, Mckesson (MCK) 30.7%, Baxter International (BAX) 44.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SKYA, MCK and BAX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.